These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10339653)

  • 21. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
    Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
    J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
    BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.
    Jones BA; Kasl SV; Howe CL; Lachman M; Dubrow R; Curnen MM; Soler-Vila H; Beeghly A; Duan F; Owens P
    Cancer; 2004 Sep; 101(6):1293-301. PubMed ID: 15368321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
    Quaranta M; Daniele A; Coviello M; Savonarola A; Abbate I; Venneri MT; Paradiso A; Stea B; Zito A; Labriola A; Schittulli F
    Tumori; 2006; 92(4):311-7. PubMed ID: 17036522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophages as independent prognostic factors in small T1 breast cancers.
    Carrio R; Koru-Sengul T; Miao F; Glück S; Lopez O; Selman Y; Alvarez C; Milikowski C; Gomez C; Jorda M; Nadji M; Torroella-Kouri M
    Oncol Rep; 2013 Jan; 29(1):141-8. PubMed ID: 23076599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
    Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
    Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
    Chen L; Li CI
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
    Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
    JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
    Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethnic differences in risk and prognostic factors for breast cancer.
    Weiss SE; Tartter PI; Ahmed S; Brower ST; Brusco C; Bossolt K; Amberson JB; Bratton J
    Cancer; 1995 Jul; 76(2):268-74. PubMed ID: 8625102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.